GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Last update: 15 May, 2:22PM

99.81

1.43 (1.45%)

Add to watchlist

Previous Close	98.38
Open	99.53
Volume	5,440,691
Avg. Volume (3M)	9,895,855
Market Cap	124,263,440,384

Price / Earnings (TTM)	20.97
Price / Earnings (Forward)	14.20
Price / Sales	4.92
Price / Book	7.30

52 Weeks Range	62.07 (-37%) — 119.96 (20%)
Earnings Date	6 Aug 2025 - 11 Aug 2025
TTM Dividend Yield	3.13%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bearish	Mixed
	Drug Manufacturers - General (Global)	Bearish	Mixed
Stock	Gilead Sciences, Inc.	Bullish	Bullish

AIStockmoo Score

1.7

Analyst Consensus	4.0
Insider Activity	-1.5
Price Volatility	2.0
Technical Moving Averages	0.0
Technical Oscillators	4.0
Average	1.70

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
GILD	124 B	3.13%	20.97	7.30
AMGN	157 B	3.17%	26.31	25.15
AZN	226 B	2.13%	29.27	6.19
SNY	122 B	4.43%	17.53	1.46
GRFS	6 B	-	28.00	0.910
BIIB	17 B	-	11.68	1.14

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Value
% Held by Insiders	0.12%
% Held by Institutions	89.68%

52 Weeks Range	62.07 (-37%) — 119.96 (20%)
Price Target Range	125.00 (25%) — 135.00 (35%)
High	135.00 (Morgan Stanley, 35.26%)	Buy
Median	127.50 (27.74%)
Low	125.00 (Oppenheimer, 25.24%)	Buy
	125.00 (Cantor Fitzgerald, 25.24%)	Buy
Average	128.75 (29.00%)
Total	4 Buy
Avg. Price @ Call	105.75

Firm	Date	Target Price	Call	Price @ Call
Morgan Stanley	25 Apr 2025	135.00 (35.26%)	Buy	103.17
Oppenheimer	25 Apr 2025	125.00 (25.24%)	Buy	103.17
Cantor Fitzgerald	22 Apr 2025	125.00 (25.24%)	Buy	105.51
JP Morgan	27 Mar 2025	130.00 (30.25%)	Buy	111.16

No data within this time range.

Date	Type	Details
01 Jun 2025	Announcement	Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
31 May 2025	Announcement	Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
23 May 2025	Announcement	ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
15 May 2025	Announcement	Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
12 May 2025	CNBC	Trump's plan to slash drug prices may struggle to get off the ground – here's what to know
07 May 2025	Announcement	Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
07 May 2025	Announcement	Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
29 Apr 2025	Announcement	Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
29 Apr 2025	Announcement	Gilead Sciences to Present at Upcoming Investor Conferences
28 Apr 2025	Announcement	Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
24 Apr 2025	Announcement	Gilead Sciences Announces First Quarter 2025 Financial Results
24 Apr 2025	CNBC	Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
21 Apr 2025	Announcement	Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
10 Apr 2025	Announcement	Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
Show more

TTM Dividend Yield	3.13%
5Y Average Dividend Yield	3.80%
Payout Ratio	65.13%
Expected Next Dividend Payment	Sep 2025

Ex Date	Announcement Date	Payment Date	Details
13 Jun 2025	22 Apr 2025	27 Jun 2025	0.79 Cash
14 Mar 2025	05 Feb 2025	28 Mar 2025	0.79 Cash
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 Cash
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 Cash
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 Cash
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 Cash
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 Cash
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 Cash
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 Cash
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 Cash
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 Cash
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 Cash
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 Cash
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 Cash
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 Cash
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 Cash
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 Cash
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 Cash
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 Cash
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 Cash
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 Cash
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 Cash
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 Cash
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 Cash
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 Cash
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 Cash
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 Cash
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 Cash
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 Cash
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 Cash
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 Cash
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 Cash
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 Cash
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 Cash
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 Cash
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 Cash
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 Cash
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 Cash
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 Cash
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 Cash
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	1.58	2	1.58
2024	3.08	4	3.33
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	20.76%
Operating Margin (TTM)	38.49%
Diluted EPS (TTM)	4.76
Quarterly Revenue Growth (YOY)	-0.30%
Quarterly Earnings Growth (YOY)	24.80%

Total Debt/Equity (MRQ)	130.79%
Current Ratio (MRQ)	1.37
Operating Cash Flow (TTM)	10.37 B
Levered Free Cash Flow (TTM)	9.99 B

Return on Assets (TTM)	12.14%
Return on Equity (TTM)	32.65%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)